Jeewan Ram Vishnoi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeewan Ram Vishnoi has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Puneet Pareek
Department of Radiation Oncology All India Institute of Medical Sciences Jodhpur India
9 shared publications - Dharma Ram Poonia
Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India
8 shared publications - Nivedita Sharma
Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India
7 shared publications - Sanjeev Misra
All India Institute of Medical Sciences, Jodhpur, India
7 shared publications Sanjeev Misra
Department of Surgical Oncology All India Institute of Medical Sciences Jodhpur India
6 shared publications- Poonam Elhence
All India Institute of Medical Sciences
5 shared publications
Latest Publications
- 16 November 2026
- Published by Wiley in World Journal of Surgery
Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial
Background: Sentinel lymph node biopsy is standard for staging clinically node‐negative (cN0) breast cancer, but the dual tracer gold‐standard radioisotope–blue dye technique is unavailable in resource‐limited settings. Fluorescein, an inexpensive, safe, visible‐light tracer, has no randomized data after neoadjuvant chemotherapy (NACT). We compared fluorescein–methylene blue with methylene blue alone for sentinel lymph node biopsy in post‐NACT cN0 patients and, secondarily, assessed the accuracy of axillary ultrasound. Methods: In this randomized pilot feasibility trial, post‐NACT cN0 breast cancer patients were randomized 1:1 to fluorescein–methylene blue (FlaB) or methylene blue alone after dye allergy testing. All patients underwent completion axillary lymph node dissection as the reference standard. Identification rate and false‐negative rate were estimated with 95% confidence intervals. Results: Of 136 patients who received NACT, 62 (45.6%) had a clinical complete nodal response and were recruited; 2 (3.2%) were excluded for methylene blue allergy, leaving 30 randomized per group, with all 60 completing the protocol. IR: 93.3% (28/30; 95% CI, 78.7–98.1) with FlaB versus 83.3% (25/30; 95% CI, 66.4–92.7) with methylene blue alone (difference, 10.0 percentage points; p = 0.23). FNR: 11.1% (2/18; 95% CI, 3.1–32.8) versus 12.5% (2/16; 95% CI, 3.5–36.0; p = 0.87). On secondary analysis, axillary ultrasound was normal in 30 of 62 patients (48.4%) and suspicious in 32 (51.6%); against final pathology, its sensitivity was 80.6%, and its negative predictive value was 76.7%; 7 of the 36 node‐positive patients (19.4%) had a sonographically normal axilla. No dye‐related adverse events occurred. Conclusion: FlaB achieved an identification rate above the 90% benchmark and a false‐negative rate comparable to radioisotope‐based dual‐tracer series. Axillary ultrasound did not reliably exclude residual nodal disease (negative predictive value 76.7%) and cannot replace pathological nodal staging after NACT. Fluorescein–methylene blue is a safe, radioisotope‐free dual‐tracer strategy for SLNB in resource‐limited settings.
- 16 November 2026
- Published by Wiley in World Journal of Surgery
Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial
Background: Sentinel lymph node biopsy is standard for staging clinically node‐negative (cN0) breast cancer, but the dual tracer gold‐standard radioisotope–blue dye technique is unavailable in resource‐limited settings. Fluorescein, an inexpensive, safe, visible‐light tracer, has no randomized data after neoadjuvant chemotherapy (NACT). We compared fluorescein–methylene blue with methylene blue alone for sentinel lymph node biopsy in post‐NACT cN0 patients and, secondarily, assessed the accuracy of axillary ultrasound. Methods: In this randomized pilot feasibility trial, post‐NACT cN0 breast cancer patients were randomized 1:1 to fluorescein–methylene blue (FlaB) or methylene blue alone after dye allergy testing. All patients underwent completion axillary lymph node dissection as the reference standard. Identification rate and false‐negative rate were estimated with 95% confidence intervals. Results: Of 136 patients who received NACT, 62 (45.6%) had a clinical complete nodal response and were recruited; 2 (3.2%) were excluded for methylene blue allergy, leaving 30 randomized per group, with all 60 completing the protocol. IR: 93.3% (28/30; 95% CI, 78.7–98.1) with FlaB versus 83.3% (25/30; 95% CI, 66.4–92.7) with methylene blue alone (difference, 10.0 percentage points; p = 0.23). FNR: 11.1% (2/18; 95% CI, 3.1–32.8) versus 12.5% (2/16; 95% CI, 3.5–36.0; p = 0.87). On secondary analysis, axillary ultrasound was normal in 30 of 62 patients (48.4%) and suspicious in 32 (51.6%); against final pathology, its sensitivity was 80.6%, and its negative predictive value was 76.7%; 7 of the 36 node‐positive patients (19.4%) had a sonographically normal axilla. No dye‐related adverse events occurred. Conclusion: FlaB achieved an identification rate above the 90% benchmark and a false‐negative rate comparable to radioisotope‐based dual‐tracer series. Axillary ultrasound did not reliably exclude residual nodal disease (negative predictive value 76.7%) and cannot replace pathological nodal staging after NACT. Fluorescein–methylene blue is a safe, radioisotope‐free dual‐tracer strategy for SLNB in resource‐limited settings.
- 15 September 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e271987
Maxillary brown tumour as the initial presentation of primary hyperparathyroidism
Brown tumours are rare skeletal manifestations of primary hyperparathyroidism (PHPT). They mimic giant cell-rich lesions and are usually found in the mandible, ribs, pelvis or long bones. Maxillary involvement is exceptionally rare. In this report, a middle-aged woman presented with right cheek swelling due to an expansile maxillary lesion initially diagnosed as a maxillary giant cell tumour, with surgery planned on that basis. Further evaluation revealed multiple skeletal lesions, markedly raised parathyroid hormone and a parathyroid adenoma. She underwent a successful parathyroid adenoma excision after which her biochemical abnormalities were resolved. The maxillary lesion was diagnosed as a brown tumour secondary to PHPT. This case highlights how maxillary brown tumours may be the first manifestation of PHPT. Early recognition through biochemical testing is crucial to avoid unnecessary aggressive surgery as definitive treatment lies in parathyroidectomy.
- 15 September 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e271987
Maxillary brown tumour as the initial presentation of primary hyperparathyroidism
Brown tumours are rare skeletal manifestations of primary hyperparathyroidism (PHPT). They mimic giant cell-rich lesions and are usually found in the mandible, ribs, pelvis or long bones. Maxillary involvement is exceptionally rare. In this report, a middle-aged woman presented with right cheek swelling due to an expansile maxillary lesion initially diagnosed as a maxillary giant cell tumour, with surgery planned on that basis. Further evaluation revealed multiple skeletal lesions, markedly raised parathyroid hormone and a parathyroid adenoma. She underwent a successful parathyroid adenoma excision after which her biochemical abnormalities were resolved. The maxillary lesion was diagnosed as a brown tumour secondary to PHPT. This case highlights how maxillary brown tumours may be the first manifestation of PHPT. Early recognition through biochemical testing is crucial to avoid unnecessary aggressive surgery as definitive treatment lies in parathyroidectomy.
- 3 June 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (8) , 2000-2009
“AR”e We Ignoring the Role of Androgen Receptor (AR) in Breast Carcinomas?
Introduction: Breast cancer, now more prevalent than lung cancer, is the most commonly diagnosed cancer globally, impacting 1 in 8 individuals and causing 2.3 million new diagnoses each year. The androgen receptor (AR) governs gene transcription, influencing differentiation, proliferation, apoptosis, and angiogenesis. Delving into AR signaling may offer opportunities to explore alternative therapeutic targets crucial for overcoming medication resistance and maximizing clinical advantages in treating breast cancer. Aim: To study AR expression across different subtypes of breast cancer and to determine its significance by establishing correlations with clinicopathological parameters. Methods: AR immunohistochemistry was conducted on 300 breast cancer patients, and its expression was analyzed in conjunction with diverse clinicopathological parameters. Results: Out of the 300 breast carcinoma patients examined, AR expression was observed in 193 patients. A statistically significant correlation was noted between AR expression and various clinical and histomorphological factors like age, breast biomarker status, Ki-67 proliferation index, histological grade, intrinsic subtype, and nodal metastasis. Conclusion: In the current study, 64.3% of patients exhibited positivity for AR. Among the 4 markers assessed (estrogen receptor, progesterone receptor, HER2 (ERBB2), and AR), AR displayed the highest frequency of expression, being positive in 193 patients (64.3%). These findings suggest that AR assessment may have potential utility, particularly in triple-negative breast cancer, and merit further prospective evaluation.
- 3 June 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (8) , 2000-2009
“AR”e We Ignoring the Role of Androgen Receptor (AR) in Breast Carcinomas?
Introduction: Breast cancer, now more prevalent than lung cancer, is the most commonly diagnosed cancer globally, impacting 1 in 8 individuals and causing 2.3 million new diagnoses each year. The androgen receptor (AR) governs gene transcription, influencing differentiation, proliferation, apoptosis, and angiogenesis. Delving into AR signaling may offer opportunities to explore alternative therapeutic targets crucial for overcoming medication resistance and maximizing clinical advantages in treating breast cancer. Aim: To study AR expression across different subtypes of breast cancer and to determine its significance by establishing correlations with clinicopathological parameters. Methods: AR immunohistochemistry was conducted on 300 breast cancer patients, and its expression was analyzed in conjunction with diverse clinicopathological parameters. Results: Out of the 300 breast carcinoma patients examined, AR expression was observed in 193 patients. A statistically significant correlation was noted between AR expression and various clinical and histomorphological factors like age, breast biomarker status, Ki-67 proliferation index, histological grade, intrinsic subtype, and nodal metastasis. Conclusion: In the current study, 64.3% of patients exhibited positivity for AR. Among the 4 markers assessed (estrogen receptor, progesterone receptor, HER2 (ERBB2), and AR), AR displayed the highest frequency of expression, being positive in 193 patients (64.3%). These findings suggest that AR assessment may have potential utility, particularly in triple-negative breast cancer, and merit further prospective evaluation.
- 3 January 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (8) , 1-9
Feasibility, Safety, Efficacy, and Surgical Utility of CO₂ Insufflation-Assisted Peritonectomy Versus Conventional Stripping in Advanced Ovarian Cancer: an Open-Label Phase II Randomized Controlled Trial
- 3 January 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (8) , 1-9
Feasibility, Safety, Efficacy, and Surgical Utility of CO₂ Insufflation-Assisted Peritonectomy Versus Conventional Stripping in Advanced Ovarian Cancer: an Open-Label Phase II Randomized Controlled Trial
- Open Access
- 16 December 2025
- Published by Springer Nature in Cardio-Oncology
- Vol. 11 (1) , 111
Redefining cardiac risk in breast radiotherapy: a substructure-based dosimetric and biomarker correlation study
This study aimed to evaluate the efficacy of the mean heart dose (MHD) as a predictor of radiation exposure to cardiac substructures and its association wi
- 16 December 2025
- Published by Springer Nature in Cardio-Oncology
- Vol. 11 (1) , 111
Open AccessRedefining cardiac risk in breast radiotherapy: a substructure-based dosimetric and biomarker correlation study
This study aimed to evaluate the efficacy of the mean heart dose (MHD) as a predictor of radiation exposure to cardiac substructures and its association wi
- 22 November 2025
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 88 (5) , 1200-1202
Carcinoma Sigmoid Colon with Double Fistula: A Rare Presentation Involving Cecum and Urinary Bladder
- 22 November 2025
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 88 (5) , 1200-1202
Carcinoma Sigmoid Colon with Double Fistula: A Rare Presentation Involving Cecum and Urinary Bladder
- 15 October 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (6) , 1-4
Preserving a Functional Foot: Limb-Salvage Surgery with Brachy Mono-Therapy for Soft Tissue Sarcoma
Soft tissue sarcomas (STS) of the foot are rare, accounting for 2–5% of musculoskeletal sarcomas, and are often associated with higher amputation rates due to limited soft tissue coverage, complex anatomy, and the functional demands of weight-bearing. We report the case of a 70-year-old woman with a myxoinflammatory fibroblastic sarcoma involving the 2nd–4th metatarsals. Limb salvage surgery was performed, consisting of en bloc resection with preservation of the metatarso-phalangeal joints, skeletal fixation with titanium plates, tendon reconstruction using tensor fascia lata, and soft-tissue coverage with an anterolateral thigh free flap. Intraoperative, interstitial brachytherapy catheters were placed, enabling 36 Gy/9 fractions safely without wound or flap complications. At 6 months, the patient was disease-free and ambulatory without disability. This case demonstrates that with multidisciplinary planning, complex reconstruction and adjuvant brachytherapy can achieve durable local control and preserve function in selected patients with foot sarcoma.
- 15 October 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (6) , 1-4
Preserving a Functional Foot: Limb-Salvage Surgery with Brachy Mono-Therapy for Soft Tissue Sarcoma
Soft tissue sarcomas (STS) of the foot are rare, accounting for 2–5% of musculoskeletal sarcomas, and are often associated with higher amputation rates due to limited soft tissue coverage, complex anatomy, and the functional demands of weight-bearing. We report the case of a 70-year-old woman with a myxoinflammatory fibroblastic sarcoma involving the 2nd–4th metatarsals. Limb salvage surgery was performed, consisting of en bloc resection with preservation of the metatarso-phalangeal joints, skeletal fixation with titanium plates, tendon reconstruction using tensor fascia lata, and soft-tissue coverage with an anterolateral thigh free flap. Intraoperative, interstitial brachytherapy catheters were placed, enabling 36 Gy/9 fractions safely without wound or flap complications. At 6 months, the patient was disease-free and ambulatory without disability. This case demonstrates that with multidisciplinary planning, complex reconstruction and adjuvant brachytherapy can achieve durable local control and preserve function in selected patients with foot sarcoma.
- Open Access
- 16 May 2025
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 19 (1) , 1-13
Short-term clinical outcomes of open, laparoscopic, and robotic-assisted rectal resections: a multicenter real-world evidence study from Indian collaborative group on rectal resections (ICGRR)
This multi-centric real-world study was carried out to assess the perioperative and histopathological clinical outcomes of rectal resections employing open, laparoscopic, and robotic-assisted techniques. A retrospective chart review was undertaken for patients who underwent rectal resections for Stages I, II, and III rectal cancer (RC) between April 2012 and August 2023. All surgical procedures were performed with the principles of total mesorectal excision (TME) or partial mesorectal excision (for tumors located higher in the rectum). The study analyzed data from 829 patients of which 314 were in the robotic-assisted group (RAS), 206 in the laparoscopic surgery group (LG), and 309 in the open-surgery group (OG). The TNM staging and location of RC were evenly distributed across the three groups. The RAS group had a significantly lower length of hospital stay than LG and OG. Compared to LG and OG, the RAS group had less blood loss and postoperative complications, but significantly longer mean operating room time. The conversion rate of the RAS group was significantly lower than that of the LG group (p = 0.03). In comparison to the OG and LG groups, the RAS group had significantly lower (p < 0.05) rates of positive circumferential resection margin (CRM). Adjuvant treatment was administered in the RAS group significantly earlier (median, 24.5 days, IQR 18–37) compared to the LG (median, 31 days, IQR 23–41) and OG (median, 32.5 days, IQR 27–42). This largest multi‑centric study by the ICRR group has validated the value of a relatively newer technology like RAS in real-world Indian settings for rectal resections.
- 16 May 2025
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 19 (1) , 1-13
Open AccessShort-term clinical outcomes of open, laparoscopic, and robotic-assisted rectal resections: a multicenter real-world evidence study from Indian collaborative group on rectal resections (ICGRR)
This multi-centric real-world study was carried out to assess the perioperative and histopathological clinical outcomes of rectal resections employing open, laparoscopic, and robotic-assisted techniques. A retrospective chart review was undertaken for patients who underwent rectal resections for Stages I, II, and III rectal cancer (RC) between April 2012 and August 2023. All surgical procedures were performed with the principles of total mesorectal excision (TME) or partial mesorectal excision (for tumors located higher in the rectum). The study analyzed data from 829 patients of which 314 were in the robotic-assisted group (RAS), 206 in the laparoscopic surgery group (LG), and 309 in the open-surgery group (OG). The TNM staging and location of RC were evenly distributed across the three groups. The RAS group had a significantly lower length of hospital stay than LG and OG. Compared to LG and OG, the RAS group had less blood loss and postoperative complications, but significantly longer mean operating room time. The conversion rate of the RAS group was significantly lower than that of the LG group (p = 0.03). In comparison to the OG and LG groups, the RAS group had significantly lower (p < 0.05) rates of positive circumferential resection margin (CRM). Adjuvant treatment was administered in the RAS group significantly earlier (median, 24.5 days, IQR 18–37) compared to the LG (median, 31 days, IQR 23–41) and OG (median, 32.5 days, IQR 27–42). This largest multi‑centric study by the ICRR group has validated the value of a relatively newer technology like RAS in real-world Indian settings for rectal resections.